TY - JOUR
T1 - Impacts of the Human Gut Microbiome on Therapeutics
AU - Vázquez-Baeza, Yoshiki
AU - Callewaert, Chris
AU - Debelius, Justine
AU - Hyde, Embriette
AU - Marotz, Clarisse
AU - Morton, James T.
AU - Swafford, Austin
AU - Vrbanac, Alison
AU - Dorrestein, Pieter C.
AU - Knight, Rob
N1 - Publisher Copyright:
© 2018 by Annual Reviews. All rights reserved.
PY - 2018/1/6
Y1 - 2018/1/6
N2 - The human microbiome contains a vast source of genetic and biochemical variation, and its impacts on therapeutic responses are just beginning to be understood. This expanded understanding is especially important because the human microbiome differs far more among different people than does the human genome, and it is also dramatically easier to change. Here, we describe some of the major factors driving differences in the human microbiome among individuals and populations. We then describe some of the many ways in which gut microbes modify the action of specific chemotherapeutic agents, including nonsteroidal anti-inflammatory drugs and cardiac glycosides, and outline the potential of fecal microbiota transplant as a therapeutic. Intriguingly, microbes also alter how hosts respond to therapeutic agents through various pathways acting at distal sites. Finally, we discuss some of the computational and practical issues surrounding use of the microbiome to stratify individuals for drug response, and we envision a future where the microbiome will be modified to increase everyone's potential to benefit from therapy.
AB - The human microbiome contains a vast source of genetic and biochemical variation, and its impacts on therapeutic responses are just beginning to be understood. This expanded understanding is especially important because the human microbiome differs far more among different people than does the human genome, and it is also dramatically easier to change. Here, we describe some of the major factors driving differences in the human microbiome among individuals and populations. We then describe some of the many ways in which gut microbes modify the action of specific chemotherapeutic agents, including nonsteroidal anti-inflammatory drugs and cardiac glycosides, and outline the potential of fecal microbiota transplant as a therapeutic. Intriguingly, microbes also alter how hosts respond to therapeutic agents through various pathways acting at distal sites. Finally, we discuss some of the computational and practical issues surrounding use of the microbiome to stratify individuals for drug response, and we envision a future where the microbiome will be modified to increase everyone's potential to benefit from therapy.
KW - metabolome
KW - microbial ecology
KW - microbiome
KW - personalized medicine
KW - precision medicine
UR - http://www.scopus.com/inward/record.url?scp=85040587727&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040587727&partnerID=8YFLogxK
U2 - 10.1146/annurev-pharmtox-042017-031849
DO - 10.1146/annurev-pharmtox-042017-031849
M3 - Review article
C2 - 28968189
AN - SCOPUS:85040587727
SN - 0362-1642
VL - 58
SP - 253
EP - 270
JO - Annual Review of Pharmacology and Toxicology
JF - Annual Review of Pharmacology and Toxicology
ER -